• Je něco špatně v tomto záznamu ?

Long-term radiographic and endocrinological outcomes of stereotactic radiosurgery for recurrent or residual nonfunctioning pituitary adenomas

A. Shaaban, C. Dumot, G. Mantziaris, S. Dayawansa, S. Peker, Y. Samanci, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdel Karim, AMN. El-Shehaby, RM. Emad Eldin, A. Ragab Abdelsalam, R. Liscak, J. May, E. Mashiach, F. De Nigris Vasconcellos, K....

. 2024 ; 141 (3) : 773-780. [pub] 20240322

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019204

OBJECTIVE: Stereotactic radiosurgery (SRS) is used for the treatment of residual/recurrent nonfunctional pituitary adenoma (NFPA). The aim of this study was to evaluate the factors related to long-term tumor control and delayed endocrinopathies following SRS. METHODS: This retrospective, multicenter study included patients with recurrent/residual NFPA treated with single-fraction SRS; they were then divided into two arms. The first arm included patients with at least 5 years of radiographic follow-up and all patients with local tumor progression. The second arm included patients with at least 5 years of endocrinological follow-up and all patients who developed endocrinopathy. Study endpoints were tumor control and new or worsening hypopituitarism after SRS and were analyzed using Cox regression and Kaplan-Meier methodology. RESULTS: There were 360 patients in the tumor control arm (median age 52.7 [IQR 42.9-61] years, 193 [53.6%] males) and 351 patients in the hypopituitarism arm (median age 52.5 [IQR 43-61] years, 186 [53.0%] males). The median follow-up in the tumor control evaluation group was 7.95 (IQR 5.7-10.5) years. Tumor control rates at 5, 8, 10, and 15 years were 93% (95% CI 90%-95%), 87% (95% CI 83%-91%), 86% (95% CI 82%-90%), and 69% (95% CI 59%-81%), respectively. The median follow-up in the endocrinopathy evaluation group was 8 (IQR 5.9-10.7) years. Pituitary function preservation rates at 5, 8, 10, and 15 years were 83% (95% CI 80%-87%), 81% (95% CI 77%-85%), 78% (95% CI 74%-83%), and 71% (95% CI 63%-79%), respectively. A margin dose > 15 Gy (HR 0.8, 95% CI 0.7-0.9; p < 0.001) and a delay from last resection to SRS > 1 year (HR 0.9, 95% CI 0.7-0.9; p = 0.04) were significant factors related to tumor control in multivariable analysis. A maximum dose to the pituitary stalk ≤ 10 Gy (HR 1.1, 95% CI 1.09-1.2; p < 0.001) was associated with pituitary function preservation. New visual deficits after SRS occurred in 7 (1.94%) patients in the tumor control group and 8 (2.3%) patients in the endocrinopathy group. Other new cranial nerve deficits post-SRS occurred in 4 of 160 patients with data in the tumor control group and 3 of 140 patients with data in the endocrinopathy group. CONCLUSIONS: SRS affords favorable and durable tumor control for the vast majority of NFPAs. Post-SRS hypopituitarism occurs in a minority of patients, but this risk increases with time and warrants long-term follow-up.

Allegheny Health Network Cancer and Department of Neurosurgery Allegheny Health Network Pittsburgh Pennsylvania

Clinical Oncology Ain Shams University Cairo Egypt

Department of Neurological Surgery Hospices Civils de Lyon France

Department of Neurological Surgery University of Virginia Charlottesville Virginia

Department of Neurosurgery Koç University School of Medicine Istanbul Turkey

Department of Neurosurgery Postgraduate Institute of Medical Education and Research Chandigarh India

Department of Radiation Oncology National Cancer Institute Cairo University Cairo Egypt

Department of Radiation Oncology The James Cancer Hospital at The Ohio State University Columbus Ohio

Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech Republic

Departments of11Neurosurgery and

Departments of15Neurosurgery and

Departments of6Neurosurgery and

Division of Neurosurgery Université de Sherbrooke Centre de Recherche du CHUS Sherbrooke Québec Canada

Dominican Gamma Knife Center and Radiology Department CEDIMAT Santo Domingo Dominican Republic

Drexel University College of Medicine Philadelphia Pennsylvania

Gamma Knife Center Cairo Nasser Institute Hospital Cairo Egypt

Neurosurgery Department Faculty of Medecine Benha University Qalubya Egypt

Neurosurgery Department Military Medical Academy Cairo Egypt

Radiation Oncology NYU Langone New York New York

Radiation Oncology University of Miami Florida

University of Pittsburgh School of Medicine Pittsburgh Pennsylvania

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019204
003      
CZ-PrNML
005      
20241024111424.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.3171/2024.1.JNS232285 $2 doi
035    __
$a (PubMed)38518285
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Shaaban, Ahmed $u 1Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
245    10
$a Long-term radiographic and endocrinological outcomes of stereotactic radiosurgery for recurrent or residual nonfunctioning pituitary adenomas / $c A. Shaaban, C. Dumot, G. Mantziaris, S. Dayawansa, S. Peker, Y. Samanci, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdel Karim, AMN. El-Shehaby, RM. Emad Eldin, A. Ragab Abdelsalam, R. Liscak, J. May, E. Mashiach, F. De Nigris Vasconcellos, K. Bernstein, D. Kondziolka, H. Speckter, R. Mota, A. Brito, SK. Bindal, A. Niranjan, LD. Lunsford, CG. Benjamin, T. Almeida, JZ. Mao, D. Mathieu, JN. Tourigny, M. Tripathi, JD. Palmer, J. Matsui, J. Crooks, RE. Wegner, MJ. Shepard, JP. Sheehan
520    9_
$a OBJECTIVE: Stereotactic radiosurgery (SRS) is used for the treatment of residual/recurrent nonfunctional pituitary adenoma (NFPA). The aim of this study was to evaluate the factors related to long-term tumor control and delayed endocrinopathies following SRS. METHODS: This retrospective, multicenter study included patients with recurrent/residual NFPA treated with single-fraction SRS; they were then divided into two arms. The first arm included patients with at least 5 years of radiographic follow-up and all patients with local tumor progression. The second arm included patients with at least 5 years of endocrinological follow-up and all patients who developed endocrinopathy. Study endpoints were tumor control and new or worsening hypopituitarism after SRS and were analyzed using Cox regression and Kaplan-Meier methodology. RESULTS: There were 360 patients in the tumor control arm (median age 52.7 [IQR 42.9-61] years, 193 [53.6%] males) and 351 patients in the hypopituitarism arm (median age 52.5 [IQR 43-61] years, 186 [53.0%] males). The median follow-up in the tumor control evaluation group was 7.95 (IQR 5.7-10.5) years. Tumor control rates at 5, 8, 10, and 15 years were 93% (95% CI 90%-95%), 87% (95% CI 83%-91%), 86% (95% CI 82%-90%), and 69% (95% CI 59%-81%), respectively. The median follow-up in the endocrinopathy evaluation group was 8 (IQR 5.9-10.7) years. Pituitary function preservation rates at 5, 8, 10, and 15 years were 83% (95% CI 80%-87%), 81% (95% CI 77%-85%), 78% (95% CI 74%-83%), and 71% (95% CI 63%-79%), respectively. A margin dose > 15 Gy (HR 0.8, 95% CI 0.7-0.9; p < 0.001) and a delay from last resection to SRS > 1 year (HR 0.9, 95% CI 0.7-0.9; p = 0.04) were significant factors related to tumor control in multivariable analysis. A maximum dose to the pituitary stalk ≤ 10 Gy (HR 1.1, 95% CI 1.09-1.2; p < 0.001) was associated with pituitary function preservation. New visual deficits after SRS occurred in 7 (1.94%) patients in the tumor control group and 8 (2.3%) patients in the endocrinopathy group. Other new cranial nerve deficits post-SRS occurred in 4 of 160 patients with data in the tumor control group and 3 of 140 patients with data in the endocrinopathy group. CONCLUSIONS: SRS affords favorable and durable tumor control for the vast majority of NFPAs. Post-SRS hypopituitarism occurs in a minority of patients, but this risk increases with time and warrants long-term follow-up.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory hypofýzy $x chirurgie $x radioterapie $x diagnostické zobrazování $7 D010911
650    12
$a radiochirurgie $x metody $x škodlivé účinky $7 D016634
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    12
$a adenom $x chirurgie $x radioterapie $x diagnostické zobrazování $7 D000236
650    12
$a lokální recidiva nádoru $7 D009364
650    _2
$a výsledek terapie $7 D016896
650    _2
$a následné studie $7 D005500
650    _2
$a hypopituitarismus $x etiologie $7 D007018
650    _2
$a reziduální nádor $7 D018365
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dumot, Chloé $u 1Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia $u 2Department of Neurological Surgery, Hospices Civils de Lyon, France
700    1_
$a Mantziaris, Georgios $u 1Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Dayawansa, Sam $u 1Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Peker, Selcuk $u 3Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey
700    1_
$a Samanci, Yavuz $u 3Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey
700    1_
$a Nabeel, Ahmed M $u 4Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u 5Neurosurgery Department, Faculty of Medecine, Benha University, Qalubya, Egypt
700    1_
$a Reda, Wael A $u 4Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Departments of6Neurosurgery and
700    1_
$a Tawadros, Sameh R $u 4Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Departments of6Neurosurgery and
700    1_
$a Abdel Karim, Khaled $u 4Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u 7Clinical Oncology, Ain Shams University, Cairo, Egypt
700    1_
$a El-Shehaby, Amr M N $u 4Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Departments of6Neurosurgery and
700    1_
$a Emad Eldin, Reem M $u 4Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u 8Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
700    1_
$a Ragab Abdelsalam, Ahmed $u 9Neurosurgery Department, Military Medical Academy, Cairo, Egypt; and
700    1_
$a Liscak, Roman $u 10Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a May, Jaromir $u 10Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Mashiach, Elad $u Departments of11Neurosurgery and
700    1_
$a De Nigris Vasconcellos, Fernando $u Departments of11Neurosurgery and
700    1_
$a Bernstein, Kenneth $u 12Radiation Oncology, NYU Langone, New York, New York
700    1_
$a Kondziolka, Douglas $u Departments of11Neurosurgery and
700    1_
$a Speckter, Herwin $u 13Dominican Gamma Knife Center and Radiology Department, CEDIMAT, Santo Domingo, Dominican Republic
700    1_
$a Mota, Ruben $u 13Dominican Gamma Knife Center and Radiology Department, CEDIMAT, Santo Domingo, Dominican Republic
700    1_
$a Brito, Anderson $u 13Dominican Gamma Knife Center and Radiology Department, CEDIMAT, Santo Domingo, Dominican Republic
700    1_
$a Bindal, Shray K $u 14University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
700    1_
$a Niranjan, Ajay $u 14University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
700    1_
$a Lunsford, L Dade $u 14University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
700    1_
$a Benjamin, Carolina Gesteira $u Departments of15Neurosurgery and
700    1_
$a Almeida, Timoteo $u 16Radiation Oncology, University of Miami, Florida
700    1_
$a Mao, Jennifer Z $u Departments of15Neurosurgery and
700    1_
$a Mathieu, David $u 17Division of Neurosurgery, Université de Sherbrooke, Centre de Recherche du CHUS, Sherbrooke, Québec, Canada
700    1_
$a Tourigny, Jean-Nicolas $u 17Division of Neurosurgery, Université de Sherbrooke, Centre de Recherche du CHUS, Sherbrooke, Québec, Canada
700    1_
$a Tripathi, Manjul $u 18Department of Neurosurgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India
700    1_
$a Palmer, Joshua David $u 19Department of Radiation Oncology, The James Cancer Hospital at The Ohio State University, Columbus, Ohio
700    1_
$a Matsui, Jennifer $u 19Department of Radiation Oncology, The James Cancer Hospital at The Ohio State University, Columbus, Ohio
700    1_
$a Crooks, Joseph $u 20Drexel University College of Medicine, Philadelphia, Pennsylvania; and
700    1_
$a Wegner, Rodney E $u 21Allegheny Health Network Cancer and Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania
700    1_
$a Shepard, Matthew J $u 21Allegheny Health Network Cancer and Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania
700    1_
$a Sheehan, Jason P $u 1Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
773    0_
$w MED00002843 $t Journal of neurosurgery $x 1933-0693 $g Roč. 141, č. 3 (2024), s. 773-780
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38518285 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111417 $b ABA008
999    __
$a ok $b bmc $g 2201820 $s 1231177
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 141 $c 3 $d 773-780 $e 20240322 $i 1933-0693 $m Journal of neurosurgery $n J Neurosurg $x MED00002843
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace